CONSUN PHARMACEUTICAL GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.45 HKD | 0.00% |
|
-3.15% | +35.22% |
| Sales 2024 * | 2.93B 404M 3.16B | Sales 2025 * | 3.33B 460M 3.59B | Capitalization | 4.94B 682M 5.33B |
|---|---|---|---|---|---|
| Net income 2024 * | 897M 124M 967M | Net income 2025 * | 1.04B 144M 1.13B | EV / Sales 2024 * | 0.77 x |
| Net cash position 2024 * | 2.69B 371M 2.9B | Net cash position 2025 * | 3.22B 445M 3.47B | EV / Sales 2025 * | 0.52 x |
| P/E ratio 2024 * |
5.41
x | P/E ratio 2025 * |
4.66
x | Employees | 3,127 |
| Yield 2024 * |
7.69% | Yield 2025 * |
9.03% | Free-Float | 44.42% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -3.15% | ||
| Current month | -3.15% | ||
| 1 month | +2.22% | ||
| 3 months | +12.76% | ||
| 6 months | +45.93% | ||
| Current year | +35.22% |
1 week
6.38
6.70
1 month
6.337.16
Current year
4.677.16
1 year
4.317.16
3 years
2.928.00
5 years
2.618.00
10 years
2.619.75
| Managers | Title | Age | Since |
|---|---|---|---|
Meng An
CEO | Chief Executive Officer | 52 | 21-03-23 |
Pei Cheng Fang
DFI | Director of Finance/CFO | 45 | 10-07-31 |
Han Xing Xu
BRD | Director/Board Member | 30 | 20-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Quan Zhu
BRD | Director/Board Member | 84 | 12-12-23 |
Zhong Shi Feng
BRD | Director/Board Member | 65 | 13-12-01 |
Yu Jun Chen
BRD | Director/Board Member | 44 | 13-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +4.30% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 6.45 | 0.00% | 600,000 |
| 24-06-06 | 6.45 | -1.68% | 2,612,700 |
| 24-06-05 | 6.56 | -1.20% | 1,166,644 |
| 24-06-04 | 6.64 | -0.45% | 823,000 |
| 24-06-03 | 6.67 | +0.15% | 478,000 |
Delayed Quote Hong Kong S.E., June 07, 2024 at 04:09 am EDT
More quotes
Consun Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The pharmaceutical products of the Company include kidney medicines, contrast medium and others. The Companyâs subsidiaries include Brilliant Reach Group Limited, Century International Develop Limited and Grand Reach Company Limited. Through its subsidiaries, the Company is also engaged in the research and development of pharmaceutical products.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.983
CNY
Average target price
7.615
CNY
Spread / Average Target
+27.27%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +35.22% | 682M | |
| +19.64% | 43.3B | |
| +21.25% | 22.22B | |
| +18.92% | 15.43B | |
| +20.14% | 14.48B | |
| +53.19% | 12.72B | |
| -0.05% | 6.79B | |
| -11.11% | 6.71B | |
| -8.87% | 5.73B | |
| +14.68% | 5.5B |
- Stock Market
- Equities
- 1681 Stock
